Oprelvekin rh IL 11 Brand Name– Neumega
What is Oprelvekin rh IL 11
Oprelvekin rh IL 11 is a recombinant version of human interleukin-11 (IL-11) derived from genetically altered Escherichia coli. Unlike endogenous IL-11, oprelvekin lacks the amino-terminal proline residue.
The biological activity of oprelvekin and endogenous IL-11 is essentially the same. Endogenous IL-11 is produced by a variety of stromal cells including fibroblasts, epithelial cells and osteoblasts and has a wide spectrum of biological activity involving the hematopoietic, lymphopoietic, hepatic, adipose, neuronal and osteoclast systems.
IL-11 belongs to a family of human growth factors, which includes granulocyte colony-stimulating factor (G-CSF), human growth hormone, and other growth factors.
Oprelvekin is used clinically to prevent severe chemotherapy-induced thrombocytopenia and to reduce the need for platelet transfusions following myelosuppressive chemotherapy for nonmyeloid malignancies.
Oprelvekin is undergoing investigation in children for the same indication.
Oprelvekin is not effective for patients undergoing bone marrow transplantation and should not be used after myeloablative chemotherapy.
Oprelvekin was approved on November 25, 1997 for patients who are at high risk for developing severe chemotherapy-induced thrombocytopenia; however, it was denied approval for use as primary prophylaxis.
Indications
- chemotherapy-induced thrombocytopenia
For the prevention of severe chemotherapy-induced thrombocytopenia and to reduce the need for platelet transfusions following myelosuppressive chemotherapy in patients with non-myeloid malignancies who are at high risk of severe thrombocytopenia
NOTE: Oprelvekin has been designated an orphan drug by the FDA for this indication.
Side Effects
- abdominal pain
- alopecia
- anemia
- angioedema
- anorexia
- antibody formation
- asthenia
- atrial fibrillation
- atrial flutter
- blurred vision
- bone pain
- candidiasis
- capillary leak syndrome
- cardiac arrest
- chest pain (unspecified)
- chills
- constipation
- cough
- dehydration
- diarrhea
- dizziness
- dysarthria
- dyspepsia
- dyspnea
- ecchymosis
- edema
- exfoliative dermatitis
- fever
- fluid retention
- flushing
- headache
- heart failure
- hypoalbuminemia
- hypocalcemia
- hypokalemia
- hypotension
- infection
- injection site reaction
- insomnia
- laryngeal edema
- myalgia
- nausea
- ocular hemorrhage
- ocular infection
- palpitations
- papilledema
- paresthesias
- pericardial effusion
- peripheral edema
- pharyngitis
- pleural effusion
- pulmonary edema
- rash
- renal failure (unspecified)
- rhinitis
- serious hypersensitivity reactions or anaphylaxis
- sinus tachycardia
- skin discoloration
- stroke
- syncope
- urticaria
- visual impairment
- vomiting
- wheezing
Monitoring Parameters
- CBC
- platelet count
- serum electrolytes
Contraindications
- acute bronchospasm
- anemia
- angioedema
- ascites
- atrial fibrillation
- atrial flutter
- brain tumor
- breast-feeding
- cardiac arrhythmias
- cardiac disease
- cerebrovascular disease
- chemotherapy
- children
- driving or operating machinery
- electrolyte imbalance
- geriatric
- heart failure
- hypokalemia
- increased intracranial pressure
- infants
- intracranial mass
- leukemia
- multiple myeloma
- oprelvekin hypersensitivity
- papilledema
- pericardial effusion
- pleural effusion
- pregnancy
- pulmonary edema
- renal disease
- renal failure
- renal impairment
- serious hypersensitivity reactions or anaphylaxis
- stroke
- urticaria
- ventricular dysfunction
- visual disturbance
Interactions
- Bumetanide
- Ethacrynic Acid
- Furosemide
- Loop diuretics
- Thiazide diuretics
- Torsemide
